ImmunityBio (IBRX) has had a tough quarter, falling by almost 19%. Despite this, there may be some hope for the stock, as the Aroon Indicator has recently triggered a bullish signal.
First, let's take a look at the earnings results for ImmunityBio. Unfortunately, there is no specific mention of earnings in the provided information. However, it is important to note that earnings reports can greatly impact the stock price of a company. A company's earnings can affect its stock price in a few ways. Positive earnings can lead to an increase in demand for a stock, while negative earnings can lead to a decrease in demand.
Moving on to the technical analysis, the Aroon Indicator is a popular indicator that can help traders identify potential changes in trend. It consists of two lines: the AroonUp line, which measures the strength of the uptrend, and the AroonDown line, which measures the strength of the downtrend. When the AroonUp line crosses above the AroonDown line, it is a bullish signal.
According to the provided information, IBRX's Aroon Indicator triggered a bullish signal on May 01, 2023. This means that the AroonUp line is above 70 while the AroonDown line is below 30, indicating that the stock could be setting up for a bullish move. In fact, historical data shows that in 168 of 188 similar instances where the Aroon Indicator showed a similar pattern, the stock moved higher in the days that followed, putting the odds of a move higher at 89%.
However, it is important to note that past performance is not always indicative of future results. While the Aroon Indicator may be indicating a potential move higher for IBRX, there are other factors that could impact the stock's performance. Additionally, the odds of a downtrend continuation for IBRX are relatively high at 58%.
While the recent Aroon Indicator signal may be a positive sign for IBRX, it is important for investors to consider all available information before making any investment decisions. The stock has had a tough quarter, and while historical data suggests a potential move higher, there are still risks involved.
The Aroon Indicator for IBRX entered a downward trend on May 16, 2025. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 271 similar instances where the Aroon Indicator formed such a pattern. In of the 271 cases the stock moved lower. This puts the odds of a downward move at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IBRX's RSI Oscillator exited the oversold zone, of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on May 15, 2025. You may want to consider a long position or call options on IBRX as a result. In of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for IBRX just turned positive on May 13, 2025. Looking at past instances where IBRX's MACD turned positive, the stock continued to rise in of 53 cases over the following month. The odds of a continued upward trend are .
IBRX moved above its 50-day moving average on May 15, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where IBRX advanced for three days, in of 242 cases, the price rose further within the following month. The odds of a continued upward trend are .
IBRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (16.210). P/E Ratio (0.000) is within average values for comparable stocks, (61.377). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.178). Dividend Yield (0.000) settles around the average of (0.023) among similar stocks. P/S Ratio (66.667) is also within normal values, averaging (281.834).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. IBRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a producer of cancer treatment products
Industry Biotechnology